Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Biodexa Pharmaceuticals Plc operates in the Healthcare sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BDRX.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). BDRX Stock Intelligence Report. [stoxpulse.com/stocks/bdrx]
Disclaimer: The information on this page about Biodexa Pharmaceuticals Plc (BDRX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Biodexa Pharmaceuticals Plc.
Join the WaitlistAI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Parker sold 576 shares
Mar 18
Merchant sold 288 shares
Mar 18
How Much Would You Have if You Had Invested $2,000...
17h ago
Tech Corner: AAPL Builds Up Tech Ecosystem
18h ago
StoxPulse AI results for BDRX: Pulse Score 51/100. Primary sentiment trends from 15 news sources and 0 SEC filings indicate a bullish outlook.
Market Cap
$733K
P/E Ratio
-148.0
EPS
—
Volume
119.8M
Avg Volume
—
Open
$0.92
Prev. Close
$0.61
Day Range
$0.80 - $1.35
50-Day Avg
$1.15
200-Day Avg
$4.96
52W High
$19.30
52W Low
$0.60
1D
+42.2%
5D
+30.3%
1M
-7.8%
3M
-65.2%
6M
-87.0%
YTD
-64.5%
1Y
-94.7%
3Y
-100.0%
5Y
-100.0%
Revenue
0.0%
Net Income
-9.0%
EPS
100.0%
Free Cash Flow
58.6%
FY 2025 vs FY 2024
Outstanding
84K
Float
62K
Free Float
73.9%
Dec 20
Jun 21
Sep 23
Sep 24
+92.4%
Apr 25
+92.2%
Sep 25
-5170443309.1%
Mar 26
Sep 26
Beat estimates 2 of 3 quarters (67%)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

How Much Would You Have if You Had Invested $2,000 In Apple When It Went Public?

Tech Corner: AAPL Builds Up Tech Ecosystem

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

The Fed Held Rates Again: Why Long-Term Investors May Not Need to Do Anything

Apple at 50: The iPhone maker 'blew a 5-year lead' on AI, but former insiders say it can still win

2,057 Shares in Apple Inc. $AAPL Acquired by Demming Financial Services Corp ADV

Apple Inc. $AAPL Stake Increased by Stableford Capital II LLC

Signal Advisors Wealth LLC Acquires 50,263 Shares of Apple Inc. $AAPL